| UHC UMR Medical and Drug | Oncology Medication Clinical Coverage – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Preventive Care Services – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Provider Administered Drugs – Site of Care – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Repository Corticotropin Injections – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Respiratory Pathogen Nucleic Acid Detection Testing – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Rhinoplasty and Other Nasal Procedures – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Spinal Fusion and Decompression – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Uplizna® (Inebilizumab-Cdon) – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Upper Extremity Prosthetic Devices – Commercial and Individual Exchange Medical Policy | 2026-04-01 |